EMN 2021 | Long-term control of myeloma treated with MABs at second relapse
Uros Markovic, MD, University of Catania, Catania, Italy, outlines the results of a retrospective analysis investigating the long-term control of disease in patients with multiple myeloma who receive monoclonal antibody (MAB) therapy at second relapse. This was a single-center study which analyzed real-world data from 102 patients. At a median follow-up of 26 months, 33 patients were alive and nine had received a further line of therapy as a result of progressive disease. At 18 months, the median overall survival (OS) for patients who received immunotherapy was 96% compared to 55.6% in patients treated with a proteasome inhibitor and lenalidomide, or 50.5% in patients treated with a pomalidomide-based regimen. Overall, the study found that patient outcomes at second relapse remained poor, however immunotherapeutic approaches were associated with longer term disease control. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Uros Markovic, MD, discloses an affiliation with Amgen.
